What is a clinical trial?

A clinical trial is a research study involving human participants designed to evaluate medical interventions — such as drugs, devices, or behavioral strategies. Trials follow a structured protocol and are registered on ClinicalTrials.gov. They progress through phases: Phase 1 (safety), Phase 2 (efficacy), Phase 3 (large-scale comparison), and Phase 4 (post-market surveillance).

How do I find clinical trials I'm eligible for?

You can search ClinicalTrials.gov or use ClinicalMetric to filter by condition, phase, or location. Each trial listing includes eligibility criteria such as age range, sex, diagnosis, and prior treatment history. Contact the study team directly or ask your physician to refer you to a relevant trial.

Are clinical trials safe to participate in?

Clinical trials are conducted under strict ethical and regulatory oversight, including IRB approval and FDA regulation in the US. All participants must give informed consent after reviewing potential risks and benefits. Phase 1 trials carry more uncertainty, while Phase 3 trials involve interventions with an established safety profile. Participation is always voluntary and you may withdraw at any time.

What are the phases of clinical trials?

Clinical trials progress through four main phases. Phase 1 tests safety and dosing in a small group (20–80 people). Phase 2 evaluates efficacy and side effects in a larger group (100–300). Phase 3 compares the intervention against standard treatments in thousands of participants. Phase 4 occurs after approval and monitors long-term effects in the general population.

Do participants get paid for joining clinical trials?

Many clinical trials offer compensation for time and travel expenses, though payment structures vary widely by study. Compensation is not intended to be coercive. Some trials also cover treatment costs for participants. Always review the consent form carefully and ask the study coordinator about any financial considerations before enrolling.

COVID-19 Long Covid Trials 2026: Post-Infection Studies and Treatment Research

Medical Notice

This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.

Summary

More than 65 million people worldwide live with Long COVID in 2026 — persistent, debilitating symptoms following SARS-CoV-2 infection that can last months to years. The NIH RECOVER program, now in its treatment trial phase after an extensive characterization period, is testing antivirals, immune modulators, and brain stimulation therapies across eight parallel randomized controlled trials. Beyond RECOVER, over 300 independent Long COVID trials are active globally. This guide explains what is being tested, the leading biological hypotheses being targeted, eligibility requirements, and how to access these studies.

Understanding Long COVID Biology: Why Multiple Trials Are Needed

Long COVID is not a single disease — it is a syndrome with multiple overlapping subtypes, each potentially driven by a different underlying mechanism. This heterogeneity explains why dozens of different treatments are being tested simultaneously and why no single therapy is expected to work for everyone. The four leading hypotheses being targeted in active clinical trials are: viral persistence (SARS-CoV-2 RNA and protein detected in gut, lymph nodes, and brain tissue months after acute infection), immune dysregulation (persistent T cell activation, autoantibodies, elevated cytokines), gut microbiome disruption, and autonomic nervous system dysfunction (POTS, orthostatic intolerance).

The Lancet-published "RECOVER-VITAL" paper (2025) found that 6 weeks of nirmatrelvir-ritonavir (Paxlovid) produced significant improvement in Long COVID symptom burden compared to placebo in patients with fatigue-predominant phenotype — providing the first Phase 3 validation that antiviral treatment benefits a subset of Long COVID patients. This result has reshaped the field, confirming viral persistence as a mechanistically meaningful target and creating urgency for longer antiviral course trials.

RECOVER Treatment Trials: What Is Being Tested

The NIH RECOVER master protocol is running eight simultaneous randomized controlled trials at sites across the United States. Current and recently completed treatment arms include:

Nirmatrelvir-ritonavir (Paxlovid) 15-day course: Testing whether extended antiviral therapy beyond the standard 5-day acute treatment course reduces Long COVID symptom burden by targeting viral persistence in reservoirs.
Baricitinib (JAK1/2 inhibitor): Targeting persistent immune activation and elevated inflammatory cytokines — the same mechanism that reduced COVID-19 mortality in the COV-BARRIER trial.
CPAP for autonomic dysfunction: Addressing the high prevalence of undiagnosed sleep-disordered breathing and orthostatic intolerance in Long COVID patients.
Transcranial magnetic stimulation (rTMS): Targeting cognitive symptoms and brain fog via non-invasive cortical stimulation, based on neuroimaging evidence of frontal lobe hypoperfusion.
Structured pacing-based rehabilitation: Testing carefully dosed activity management (avoiding post-exertional malaise triggers) versus standard physical therapy for fatigue and function.
Low-dose naltrexone (LDN): Targeting microglial activation and neuroinflammation based on small pilot studies showing symptom improvement in post-viral syndromes.

Independent Long COVID Trials Beyond RECOVER

BC007 (Berlin Cures) is a nucleic acid aptamer that neutralizes pathogenic autoantibodies against G-protein coupled receptors, which are elevated in a subset of Long COVID patients and associated with dysautonomia and cognitive symptoms. Phase 2 trials are running in Germany and the UK. Low-dose hydrocortisone (adrenal support for Long COVID HPA axis dysfunction) is in Phase 2 at King's College London. Hyperbaric oxygen therapy (HBOT) has shown improvements in cognitive performance and brain perfusion in Israeli Phase 2 trials (Efrati et al.) and is now in Phase 3 evaluation in the US and Canada.

Ivabradine (heart rate-lowering agent for POTS) is in Phase 2 for autonomic Long COVID, while beta blockers, midodrine, and fludrocortisone are being compared in a POTS symptom management platform trial at Vanderbilt. Microbiome restoration therapies (FMT, precision probiotics) are in Phase 2 for fatigue-predominant Long COVID based on evidence of persistent gut dysbiosis. The STIMULATE-ICP trial in the UK is testing a three-drug combination of atorvastatin, colchicine, and aspirin for their combined anti-inflammatory and vascular effects.

Who Qualifies for Long COVID Trials in 2026

Eligibility criteria vary by trial but common requirements include: documented prior SARS-CoV-2 infection (PCR, antigen, or positive serology/antibody test), persistent symptoms for at least 12 weeks after acute illness, specific symptom profiles (fatigue-predominant, cognitive-predominant, or autonomic dysfunction-predominant depending on trial), and adequate functional status to complete study procedures. Many trials explicitly require that symptoms began after a clearly documented COVID infection, to distinguish Long COVID from pre-existing conditions.

Exclusion criteria often include: current use of immunosuppressive medications (for immune-targeting trials), active autoimmune disease, prior COVID vaccination failure to prevent infection versus post-infection course, and certain psychiatric conditions. Vaccination status is recorded as a covariate but is generally not an exclusion criterion — vaccinated individuals who developed Long COVID after breakthrough infections are eligible for most studies.

How to Enroll in Long COVID Research

The RECOVER patient portal (recovercovid.org) provides a site finder for all RECOVER trials and allows online pre-screening. Patient advocacy organizations including Body Politic, Long COVID Alliance, Long COVID Support, Survivor Corps, and the COVID Long-Haulers Association maintain updated lists of open studies and provide peer navigation support. Many RECOVER sub-studies offer decentralized participation options with remote visits and wearable device monitoring, which is critical for participants with post-exertional malaise who cannot easily attend multiple in-person clinic visits.

ClinicalTrials.gov searches for "Post-Acute Sequelae of SARS-CoV-2 Infection" or "Long COVID" with "Recruiting" status return 300+ active studies globally. The WHO clinical trial search portal (apps.who.int/trialsearch) provides international coverage for patients outside the US. Academic medical centers with dedicated Long COVID clinics — Yale, UCSF, Mayo Clinic, Johns Hopkins, Columbia — often have the broadest access to research studies and can provide referrals to affiliated trials.

Key Takeaways

RECOVER-VITAL confirmed that 6 weeks of nirmatrelvir-ritonavir significantly reduced Long COVID symptom burden versus placebo in fatigue-predominant patients — the first Phase 3 validation of viral persistence as a treatment target.
RECOVER is running 8 simultaneous RCTs testing antivirals, JAK inhibitors, rTMS, CPAP, pacing-based rehabilitation, and low-dose naltrexone — reflecting genuine biological heterogeneity in Long COVID mechanisms.
Independent trials are testing BC007 (autoantibody neutralizer), hyperbaric oxygen (Phase 3 in US/Canada), FMT, and ivabradine for POTS — targeting the autoimmune and autonomic subtypes of Long COVID.
Eligibility generally requires documented prior COVID infection and 12+ weeks of persistent symptoms; vaccination status is typically not an exclusion criterion.
RECOVER offers remote/decentralized participation options for patients with post-exertional malaise; patient advocacy organizations provide navigation support for accessing and enrolling in trials.